Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

被引：0

作者：

Strosberg, J. ^{[1
]}

Wolin, E. ^{[2
]}

Chasen, B. ^{[3
]}

Kulke, M. ^{[4
]}

Bushnell, D. ^{[5
]}

Caplin, M. ^{[6
]}

Baum, R. P. ^{[7
]}

Hobday, T. ^{[8
]}

Hendifar, A. ^{[9
]}

Oberg, K. ^{[10
]}

Ruszniewski, P. ^{[11
,12
]}

Krenning, E. ^{[13
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Univ Iowa, Iowa City, IA USA

[6] Royal Free Hosp, London, England

[7] Zent Klin, Bad Berka, Germany

[8] Mayo Clin, Coll Med, Rochester, NY USA

[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[10] Uppsala Univ, Univ Hosp, Uppsala, Sweden

[11] Hop Beaujon, Clichy, France

[12] Paris Diderot Univ, Clichy, France

[13] Erasmus MC, Rotterdam, Netherlands

来源：

关键词：

177lu-dotatate; prrt; net; quality of life;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

K22

引用

页码：260 / 260

页数：1